These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3084315)

  • 1. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion.
    Mauerhoff T; Ketelslegers JM; Lambert AE
    Diabete Metab; 1986 Feb; 12(1):34-8. PubMed ID: 3084315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients.
    Kyllästinen M; Groop L
    Ann Clin Res; 1985; 17(3):100-4. PubMed ID: 3931537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
    Massi-Benedetti M; Herz M; Pfeiffer C
    Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy--results of a one-year double blind study].
    Lundershausen R; Orban S; Pissarek D; Panzram G
    Wien Klin Wochenschr; 1987 Sep; 99(17):603-8. PubMed ID: 3118579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.
    Raptis SA; Hatziagelaki E; Dimitriadis G; Draeger KE; Pfeiffer C; Raptis AE
    Exp Clin Endocrinol Diabetes; 1999; 107(6):350-5. PubMed ID: 10543411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
    Cooper MB; Al Majali K; Bailey CJ; Betteridge DJ
    Clin Endocrinol (Oxf); 2008 May; 68(5):738-46. PubMed ID: 17980009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of combined treatment with glibenclamide and insulin in secondary sulfonylurea failure. A controlled multicenter double-blind clinical trial].
    Bachmann W; Lotz N; Mehnert H; Rosak C; Schöffling K
    Dtsch Med Wochenschr; 1988 Apr; 113(16):631-6. PubMed ID: 3129273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].
    Haupt E; Putschky F; Zoltobrocki M; Schöffling K
    Dtsch Med Wochenschr; 1984 Feb; 109(6):210-3. PubMed ID: 6421561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.
    Skrapari I; Perrea D; Ioannidis I; Karabina SA; Elisaf M; Tselepis AD; Karagiannacos P; Katsilambros N
    Diabet Med; 2001 Oct; 18(10):781-5. PubMed ID: 11678967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay.
    Matsuda A; Kuzuya T; Sugita Y; Kawashima K
    Horm Metab Res; 1983 Sep; 15(9):425-8. PubMed ID: 6416980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transdermal administration of insulin in type II diabetics. Results of a clinical pilot study].
    Liedtke RK; Sorger M; Merk F; Vetter H
    Arzneimittelforschung; 1990 Aug; 40(8):884-6. PubMed ID: 2242080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
    Landstedt-Hallin L; Adamson U; Arner P; Bolinder J; Lins PE
    Diabetes Care; 1995 Aug; 18(8):1183-6. PubMed ID: 7587856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity.
    Kabadi UM; McCoy S; Birkenholz M; Kabadi M
    Diabet Med; 1995 Oct; 12(10):880-4. PubMed ID: 8846678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
    Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
    Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.
    Landstedt-Hallin L; Adamson U; Lins PE
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3140-5. PubMed ID: 10487677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J; Spengler M
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination treatment with insulin and sulfonylurea. Results of a 5-year study].
    Holländer E
    Z Gesamte Inn Med; 1989 May; 44(9):261-4. PubMed ID: 2662659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.